source
- MapLight Therapeutics' mid-stage schizophrenia trial shows modest improvement but shares plunge two-thirdsMapLight Therapeutics announced that its experimental schizophrenia drug met its primary endpoint in a mid-stage study, delivering an average 4.5‑point reduction on the PANSS symptom scale after fi…
- FTC sues Hims & Hers over alleged health data sharing and deceptive billing practicesThe Federal Trade Commission filed a lawsuit against Hims & Hers, a telehealth company based in San Francisco, accusing it of improper handling of patient information. According to the complaint,…